Purple Biotech Ltd ADR PPBT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if PPBT is a good fit for your portfolio.
News
-
Purple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting
-
Purple Biotech to Present New Data On its Oncology Drug NT219 at AACR 2024
-
Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technology
-
Purple Biotech Reports Fourth Quarter and Full-Year 2023 Financial Results
-
Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024
-
Purple Biotech Convenes a Head & Neck Cancer Scientific Advisory Board in Preparation for NT219 Phase 2 Trial
-
Purple Biotech Reaches Recommended Phase 2 Dose for NT219
Trading Information
- Previous Close Price
- $0.52
- Day Range
- $0.48–0.54
- 52-Week Range
- $0.30–2.08
- Bid/Ask
- $0.48 / $0.50
- Market Cap
- $12.74 Mil
- Volume/Avg
- 176,664 / 153,926
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219 and CM24.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 20
- Website
- https://www.purple-biotech.com
Valuation
|
Metric
|
PPBT
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 2.15 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
PPBT
Financial Strength
|
Metric
|
PPBT
|
|---|---|
Quick Ratio | 2.15 |
Current Ratio | 2.20 |
Interest Coverage | −364.20 |
Quick Ratio
PPBT
Profitability
|
Metric
|
PPBT
|
|---|---|
Return on Assets (Normalized) | −45.08% |
Return on Equity (Normalized) | −161.03% |
Return on Invested Capital (Normalized) | −53.14% |
Return on Assets
PPBT
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Dtqvbmmbh | Wljq | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Jzfybmzgs | Dzxpsv | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Rplgxgky | Vgrytq | $97.8 Bil | |
MRNA
| Moderna Inc | Dfyjnpzc | Vyh | $41.3 Bil | |
ARGX
| argenx SE ADR | Tttgbmvbx | Zcfb | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Zbgnhwvh | Fmpj | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Bhdngfthx | Qbvdcc | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Rxjhqmdrs | Nwyyr | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Shcljmydyh | Gkssmn | $12.5 Bil | |
INCY
| Incyte Corp | Vbjbcfdp | Hvdxmp | $11.6 Bil |